Skip to main content
Devonian Health Group Inc logo

Devonian Health Group Inc — Investor Relations & Filings

Ticker · GSD TSXV Manufacturing
Open in API
Filings indexed 382 across all filing types
Latest filing 2025-06-26 Interim / Quarterly Rep…
Country CA Canada
Listing TSXV GSD

About Devonian Health Group Inc

https://groupedevonian.com/

Devonian Health Group Inc. is a clinical-stage botanical pharmaceutical company specializing in the development of novel prescription therapeutic solutions for unmet medical needs. The core business involves late-stage prescription botanical drugs targeting fibroinflammatory autoimmune diseases, with a focus on gastrointestinal, dermatological, and hepatologic conditions. The company utilizes a broad-based technology platform, originating from over 20 years of research, to develop therapies that target multiple cellular pathways and regulate genes linked to these diseases. Its pipeline includes the lead product candidate, Thykamine, currently in Phase 3 clinical trials. Devonian also develops high-value dermatological products alongside its core drug development activities.

Recent filings

Filing Released Lang Actions
Interim financial statements/report – English.pdf
Interim / Quarterly Report Classification · 1% confidence The document is titled 'Interim Condensed Consolidated Financial Statements' for the three-month and nine-month periods ended April 30, 2025. It contains comprehensive financial statements (Statement of Financial Position, Statement of Net Loss, Statement of Changes in Equity, Statement of Cash Flows) and detailed explanatory notes. It is a formal quarterly/interim financial report, not an announcement or a summary, and meets the criteria for an Interim/Quarterly Report (IR). 9M 2025
2025-06-26 English
52-109FV2 - Certification of interim filings - CEO (F).pdf
Regulatory Filings Classification · 1% confidence The document is “Form 52-109FV2R – Certification of Interim Filings” (Venture Issuer Basic Certificate) filed by the CEO to accompany the interim financial report and MD&A. It does not contain the interim financial statements themselves (so it’s not an Interim/Quarterly Report) but is a statutory certification under Canadian securities regulation. No other specific category covers NI 52-109 certificates, so it defaults to a general regulatory filing.
2025-06-26 English
52-109FV2 - Certification of interim filings - CFO (F).pdf
Regulatory Filings Classification · 1% confidence The document is a Form 52-109FV2R certification filed alongside the interim financial report and interim MD&A for the period ended April 30, 2025. It is a regulatory compliance certificate under Canadian securities rules (NI 52-109) rather than the interim report itself. It does not announce dividend, governance changes, financing, etc., nor is it the full interim or annual report. Therefore, it falls into the fallback category of a miscellaneous regulatory filing.
2025-06-26 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 1% confidence The document is an attestation under Canadian National Instrument 52-109 for an emerging issuer’s interim financial and MD&A filings (Annexe 52-109AE2N). It is a regulatory certificate accompanying the interim report rather than the interim financial report itself or a shareholder meeting presentation, earnings announcement, or other specific filing. No other specialized category applies, so it falls under the general Regulatory Filings fallback (RNS).
2025-06-26 French
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 1% confidence The document is a standalone attestation (certification) by the CFO under Canadian NI 52-109 for interim financial documents for the period ended April 30, 2025. It does not contain the interim financial statements themselves, nor is it a summary of results or an investor presentation. It is a required regulatory certificate filing and does not fit the defined categories like Quarterly Report (IR) or Management Discussion (MDA), so it falls into the fallback category of Regulatory Filings (RNS).
2025-06-26 French
News release - French.pdf
Board/Management Information Classification · 1% confidence The document is a press release announcing the appointment of a new CEO (Dr André Boulet) and changes to the executive team, as well as the approval of share option grants. This is a clear announcement of senior management changes, fitting the “Board/Management Information” category (MANG).
2025-06-10 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.